185 Results
Sort By:
Published on April 1, 2024
Investor appetite is growing for startups that can make proteomics faster, cheaper, and more informative for use in precision medicine. Here are five proteomics innovators that have raised significant investments in the last few years. The growth of genomics has proven instrumental to the adoption of precision medicine by allowing…
Published on October 18, 2023
The discovery of cancer biomarkers is a critical component to improving patient outcomes. Key biomarkers not only determine what drives tumor growth, they also facilitate the development of treatment strategies that specifically target the tumor. However, biomarker discovery requires deep tissue characterization. Currently, cancer biomarkers are typically limited in their…
Published on October 11, 2023
Researchers have identified more than 1,000 functional new druggable cancer drug targets using a combination protocol involving gene base editing and chemical proteomics. The research, published in Nature Chemical Biology, focused on editing thousands of bases on more than 1,750 genes known to be correlated with cancer development. The work…
Published on August 9, 2023
A new study describes a new diagnostic approach that could help identify the 15% of women with ovarian cancer whose tumors are intrinsically refractory to standard platinum-based therapies, the most common type of chemotherapy for the disease. Most ovarian cancers are very sensitive to platinum therapy, at least initially. However,…
Published on April 10, 2023
The concept of precision medicine has been a goal of medicine for decades. Accordingly, oncologists have employed patient selection strategies using genetic biomarkers, a successful approach for a small subset of cancers. For the majority of patients with cancer, however, treatment success has been limited and the field is now…
Published on April 10, 2023
Sponsored content brought to you by Over the years, cancer researchers have tried to characterize the complex network of protein and cellular interactions that support or inhibit tumor growth. Spatial context provides a new perspective that is rapidly improving scientists’ understanding of how cancers progress. Immunohistochemistry (IHC) assays have long…
Published on January 3, 2023
By integrating spatial transcriptomics with protein markers researchers have substantially improved resolution of differential gene expression analysis across tissue regions. Spatial PrOtein and Transcriptome Sequencing (SPOTS) reveals the activities of specific types of cells in much more detail than unimodal measurements. This method thus allows creation of data-rich maps of…
Published on June 9, 2022
It’s been a whirlwind couple of weeks for new NGS company Ultima Genomics. Fresh off emerging from stealth mode by announcing $600 million in venture funding last week and a bioRxiv preprint that broke a few days before detailing its sequencing technology, the company announced Wednesday it will collaborate with…
Published on February 16, 2022
Ovarian cancer is the most lethal gynecologic malignancy and, despite their promise, immunotherapies have only modest efficacy against it. Now researchers at the University of Helsinki have uncovered new evidence about how tumor cells interact with the immune system in this particularly aggressive type of cancer, which affects about 240,000…
Published on January 6, 2022
Next-generation sequencing (NGS) market leader Illumina announced on Wednesday a co-development deal with proteomic analysis company SomaLogic that will incorporate the SomaScan Proteomics Assay onto current and future high-throughput NGS platforms from Illumina. The deal comes amid an increasing focus on multiomic approaches to identifying complex biomarkers of cancer and…
Published on July 22, 2021
The complexity of ‘omics offers challenges and opportunities. That’s particularly true of proteomics and metabolomics. About 20,000 proteins make up the encoded human proteome, and post-translational modifications add many more. The human metabolome—the intermediates or end products of reactions—consists of more than 100,000 small molecules. The makeup of any area…
Published on July 22, 2021
Sponsored content brought to you by What is the mission of Precision Biomarker Laboratories (PBL)? Jennifer Van Eyk, PhDDirectorPrecision Biomarker Labs Precision Biomarker Laboratories is focused on releasing the power of precise proteomics by utilizing our growing understanding of the proteome to transform how medicine…
Published on June 29, 2021
A blood test has been developed that allows detection and screening of Alzheimer’s disease (AD) for the first time, with an accuracy level of over 96%, according to a report from researchers at Hong Kong University of Science and Technology (HKUST). “With the advancement of ultrasensitive blood-based protein detection technology,…
Published on June 16, 2021
Sponsored content brought to you by Functional proteomics is at the forefront of current medical research and has the potential to greatly accelerate therapy development for many complex diseases. IsoPlexis addresses many of the core issues facing researchers by driving the convergence of dynamic proteomics and single-cell biology. IsoPlexis’ multifaceted…
Published on October 21, 2019
Sponsor: In developing immunotherapies, processes and biomarkers are made more complex by the highly heterogenous T cells that form the basis for the therapeutic product, or that drive the anti-tumor response in various checkpoint and antibody based immunotherapies. IsoPlexis’ next generation systems provide actionable potency, safety, and patient difference metrics…